Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Neoplasms, Breast
Interventions: DRUG: Investigational Cancer Drug
Sponsor: GlaxoSmithKline